慢性髓性白血病一线第二代酪氨酸激酶抑制剂治疗后的长期结局:不耐受与耐药的管理
该回顾性研究分析了106例接受一线第二代酪氨酸激酶抑制剂(2GTKI)治疗的慢性髓性白血病慢性期(CML-CP)患者,中位随访91个月。45例(42.4%)转换为替代TKI,其中28例(26.4%)因不耐受、17例(16%)因耐药。耐药患者后续结局较差,7年总生存(OS)显著低于不耐受患者和持续一线2GTKI治疗者。
要点
- 一线2GTKI治疗失败时,不耐受患者换用另一种2GTKI可有效管理,耐药患者需早期考虑3/4GTKI。
- 耐药患者7年OS为66.1%,显著低于不耐受患者(100%)和持续一线2GTKI者(97.9%)(p=0.001)。
- 不耐受患者虽多需多次换药且起效较慢,尤其换用二线伊马替尼者,但仍可获得深层分子学反应(DMR)。
核心结论
- 一线2GTKI治疗失败是现代CML治疗中的挑战性问题;不耐受可通过换用另一种2GTKI有效管理,但耐药需早期考虑3/4GTKI。
研究设计与样本
- 回顾性分析106例接受一线2GTKI治疗的CML-CP患者,中位随访91个月。
主要发现
- 45例(42.4%)转换为替代TKI,其中28例(26.4%)因不耐受、17例(16%)因耐药。
- 持续一线2GTKI治疗者多数获得DMR,15例(14.1%)处于无治疗缓解(TFR)。
- 不耐受患者也可获得DMR,但多数需多次TKI更换且起效较慢,尤其换用二线伊马替尼者。
- 耐药患者结局较差,替代二线2GTKI治疗失败并需要3/4GTKI和/或异基因造血干细胞移植(alloSCT)。
- 耐药患者7年OS为66.1%,显著低于不耐受患者(100%)和持续一线2GTKI治疗者(97.9%)(p=0.001)。
临床怎么用
- 作者认为,一线2GTKI不耐受可通过换用另一种2GTKI有效管理,但耐药需早期考虑3/4GTKI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Second-generation tyrosine kinase inhibitors (2GTKI) are more effective in inducing rapid molecular responses than imatinib when used first-line in patients with chronic myeloid leukemia in chronic phase (CML-CP). However, failure of first line-2GTKI (1L-2GTKI) still occurs and there is no consensus regarding subsequent management. We retrospectively analyzed the outcome of 106 CML-CP patients treated with 1L-2GTKI and with a median follow-up of 91 months. 45 patients (42.4%) switched to an alternative TKI, 28 for intolerance (26.4%) and 17 (16%) for resistance. Most patients who remained on 1L-2GTKI achieved deep molecular responses (DMR) and 15 (14.1%) are in treatment-free remission (TFR). Intolerant patients also obtained DMR, although most required multiple TKI changes and were slower to respond, particularly if treated with 2L-imatinib. Inferior outcomes were observed in resistant patients, who failed alternative 2L-2GTKI and required 3/4GTKI and/or allogeneic hematopoietic stem cell transplant (alloSCT). 7yr-OS was significantly lower for these individuals (66.1%) than for intolerant patients and those who remained on 1L-2GTKI (100% and 97.9%, respectively; p = 0.001). It is apparent that failure of 1L-2GTKI is a challenging problem in modern CML therapy. Intolerance can be effectively managed by switching to an alternative 2GTKI, but resistance requires early consideration of 3/4GTKI.
引用
- Claudiani S, Chughtai F, Khan A, et al. Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance. Leukemia. 2024. PMID: 38424138. doi:10.1038/s41375-024-02187-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。